Particle.news

Download on the App Store

Sanofi’s $20 Billion US Investment Draws Criticism in France

Under pressure from Donald Trump’s tariff threats, Sanofi pledges significant US investments, sparking concerns over French industrial sovereignty.

Le laboratoire Sanofi a bénéficié de plus d’un milliard d’euros de crédit impôt recherche en dix ans.
Image
Image
Image

Overview

  • Sanofi has committed at least $20 billion to US factories and research by 2030, responding to tariff and pricing threats from Donald Trump.
  • The French Economy Minister labeled the move a 'bad signal,' emphasizing the need for investment in Europe and France.
  • Labor unions warn of a potential shift of research and production to the US, risking Europe's pharmaceutical industry strength.
  • Sanofi's announcement follows similar US investment pledges by global pharmaceutical firms like Novartis and Eli Lilly under US geopolitical pressure.
  • Despite no immediate cuts to French investments, concerns grow over a gradual reallocation of resources to more profitable markets like the US.